AstraZeneca says 4th-Q earns triple on cancer drugs sales
AstraZeneca, co-developer of one of the first COVID-19 vaccines to be authorized for widespread use, says fourth-quarter earnings more than tripled amid strong sales of cancer drugs
AstraZeneca co-developer of one of the first COVID-19 vaccines to be authorized for widespread use, says fourth-quarter earnings more than tripled amid strong sales of its cancer drugs.
The Anglo-Swedish company said Thursday that net income rose to $1.01 billion from $313 million in the same quarter a year earlier.
Drug sales increased 11% to $7.41 billion, driven by a 24% increase in cancer treatments.
The company posted $2 million of revenue from its COVID-19 vaccine, which it has pledged to supply on a non-profit basis during the pandemic, and said it would begin reporting sales of the vaccine separately beginning in the next quarter.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.